Skip to main content

Catalyst Calendar

Scope

Wed, Aug 12, 2026

1 updates
CNTB
4:05 PM

Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update

– Completed enrollment in Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD – – Expect to report topline results from both Phase 2 Seabreeze STAT studies in September 2026 – – Cash runway expected for a period of at least one year from the date of this release – SAN DIEGO,

Enrollment • Phase 2Enrollment milestone Tue, Jun 30, 2026connectbiopharm.com

Wed, Jun 17, 2026

1 updates
CNTB
9:00 AM

Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma

– On track to also complete enrollment in the Seabreeze STAT COPD study this month – – Expect to report topline data from Seabreeze STAT Asthma study in early September 2026 – – Strong balance sheet with cash runway into 2H 2027 – SAN DIEGO, June 17, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma

Enrollment • Phase 2Topline data expected early September 2026 Tue, Sep 1, 2026connectbiopharm.com